NASDAQ: KALAKala Bio Inc Stock
$0.78+0.02 (+2.63%)
Updated Oct 31, 2025
KALA Price
$0.78
Fair Value Price
N/A
Market Cap
$5.03M
52 Week Low
$0.74
52 Week High
$20.60
P/E
-0.1x
P/B
0.88x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$35.65M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
7.45
Operating Cash Flow
-$27M
Beta
0.89
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
KALA Overview
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KALA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
KALA
Ranked#54 of 57
Ranked#54 of 57
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.82 | A | |
| $1.92 | A | |
| $29.37 | A |
Be the first to know about important KALA news, forecast changes, insider trades & much more!
KALA News
Overview
Due Diligence Score
–
Industry Average (26)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KALA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KALA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
KALA is good value based on its book value relative to its share price (0.88x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.21x)
P/B vs Industry Valuation
KALA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more KALA due diligence checks available for Premium users.
Valuation
KALA fair value
Fair Value of KALA stock based on Discounted Cash Flow (DCF)
Price
$0.78
Fair Value
$3.43
Undervalued by
77.25%
KALA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KALA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.1x
Industry
-14.71x
Market
41.65x
KALA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.88x
Industry
2.21x
KALA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KALA's financial health
Profit margin
Revenue
$0.0
Net Income
-$8.9M
Profit Margin
0%
KALA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$48.3M
Liabilities
$42.5M
Debt to equity
7.45
KALA's short-term assets ($45.72M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KALA's short-term assets ($45.72M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KALA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KALA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.8M
Investing
$0.0
Financing
-$135.0k
KALA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KALA vs Pharmaceutical Stocks
Kala Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.